Articles

Roche’s Bispecific Antibody Columvi Gains Edge On AbbVie And Genmab’s Epkinly Following Latest Data

Oil & Gas / United States / Tue 23 Apr, 2024

Key View

  • Roche’s latest Columvi data will support the drug’s full approval in the US and Europe.
  • Approval as an earlier line treatment will give Roche an edge over AbbVie and Genmab’s Epkinly.
  • Bispecific therapies will continue to attract interest from cancer drugmakers.

Roche’s latest Columvi (glofitamab) data will support the drug’s

Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.